212 related articles for article (PubMed ID: 32376801)
1. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
Zhang Y; Keenan A; Dai DF; May KS; Anderson EE; Lindorfer MA; Henrich JB; Pitcher GR; Taylor RP; Smith RJ
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376801
[TBL] [Abstract][Full Text] [Related]
2. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.
Ruseva MM; Takahashi M; Fujita T; Pickering MC
Clin Exp Immunol; 2014 Apr; 176(1):84-92. PubMed ID: 24279761
[TBL] [Abstract][Full Text] [Related]
3. Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.
Zanchi C; Locatelli M; Corna D; Cerullo D; Fishilevich E; Desai D; Rottoli D; Donadelli R; Noris M; Zoja C; Remuzzi G; Benigni A
Mol Immunol; 2023 Sep; 161():25-32. PubMed ID: 37481826
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy.
Zanchi C; Locatelli M; Cerullo D; Aumiller V; Corna D; Rottoli D; Schubert S; Noris M; Tomasoni S; Remuzzi G; Zoja C; Benigni A
Mol Immunol; 2024 Apr; 168():10-16. PubMed ID: 38368725
[TBL] [Abstract][Full Text] [Related]
5. Homodimeric Minimal Factor H:
Kamala O; Malik TH; Hallam TM; Cox TE; Yang Y; Vyas F; Luli S; Connelly C; Gibson B; Smith-Jackson K; Denton H; Pappworth IY; Huang L; Kavanagh D; Pickering MC; Marchbank KJ
Front Immunol; 2021; 12():752916. PubMed ID: 34956184
[TBL] [Abstract][Full Text] [Related]
6. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
7. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
8. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
9. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.
Ruseva MM; Vernon KA; Lesher AM; Schwaeble WJ; Ali YM; Botto M; Cook T; Song W; Stover CM; Pickering MC
J Am Soc Nephrol; 2013 Jan; 24(1):43-52. PubMed ID: 23184055
[TBL] [Abstract][Full Text] [Related]
10. Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina.
Williams JA; Stampoulis D; Gunter CE; Greenwood J; Adamson P; Moss SE
PLoS One; 2016; 11(8):e0161898. PubMed ID: 27564415
[TBL] [Abstract][Full Text] [Related]
11. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
12. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.
Gilmore AC; Zhang Y; Cook HT; Lavin DP; Katti S; Wang Y; Johnson KK; Kim S; Pickering MC
Kidney Int; 2021 Feb; 99(2):396-404. PubMed ID: 33129896
[TBL] [Abstract][Full Text] [Related]
13. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
[TBL] [Abstract][Full Text] [Related]
14. Dengue virus and the complement alternative pathway.
Carr JM; Cabezas-Falcon S; Dubowsky JG; Hulme-Jones J; Gordon DL
FEBS Lett; 2020 Aug; 594(16):2543-2555. PubMed ID: 31943152
[TBL] [Abstract][Full Text] [Related]
15. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.
Chauvet S; Roumenina LT; Aucouturier P; Marinozzi MC; Dragon-Durey MA; Karras A; Delmas Y; Le Quintrec M; Guerrot D; Jourde-Chiche N; Ribes D; Ronco P; Bridoux F; Fremeaux-Bacchi V
Front Immunol; 2018; 9():2260. PubMed ID: 30333829
[TBL] [Abstract][Full Text] [Related]
16. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
17. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
[No Abstract] [Full Text] [Related]
18. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
Perkins SJ
Adv Chronic Kidney Dis; 2020 Mar; 27(2):120-127.e4. PubMed ID: 32553244
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
20. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
